Ipsen: encouraging data on Cabometyx expected at ASCO
(CercleFinance.com) - The pharmaceutical group Ipsen announces that encouraging data will be presented for its Cabometyx (cabozantinib) in a variety of cancer types at the American Society of Clinical Oncology's annual meeting (ASCO 2022), to be held from 3 to 7 June.
Data presented will include results in metastatic non-small cell lung cancer, as well as established indications in advanced renal cell carcinoma and radioiodine-refractory differentiated thyroid cancer.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
Data presented will include results in metastatic non-small cell lung cancer, as well as established indications in advanced renal cell carcinoma and radioiodine-refractory differentiated thyroid cancer.
Copyright (c) 2022 CercleFinance.com. All rights reserved.